ArticleAging2024
Amyloid beta biomarker for dementia detection by hyperspectral ophthalmoscope images.
Article in Aging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of Confocal Multispectral Imaging Using a Common Commercial Device and Application in a Healthy Aging Mouse Model.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating prevalence and economic burden of dementia underscore the urgency for innovative detection methods. This study investigates the potential of hyperspectral imaging (HSI) to detect dementia by analyzing retinal changes associated with amyloid beta (Aβ) formations. Leveraging a dataset of 3,256 ophthalmoscopic images from 137 participants aged 60 to 85 years, categorized into dementia and non-dementia groups via the Mini-Mental State Examination (MMSE), we extracted features from five key regions of interest (ROIs) identified for their pronounced changes in Aβ biomarkers. The analysis revealed that gender does not significantly influence dementia levels, and no substantial spectral differences were observed within the 380 nm to 600 nm wavelength range. However, significant variations in spectral reflection intensity were noted between 600 nm and 780 nm across both genders, suggesting a potential avenue for distinguishing stages of dementia. Despite the impact of diabetes on the vascular system, its stages did not significantly influence dementia development. This research highlights the utility of HSI in identifying dementia-related retinal changes and calls for further exploration into its effectiveness as a diagnostic tool, potentially offering a non-invasive method for early detection of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.